Clinical trials: Dry Eye Disease, open to volunteers
Ocular Graft Versus Host Disease
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence…
- Trial name
- NCT07118254
- Testing
- rhPRG4 450ug/ml, Vehicle Control
- Where
- 3 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Lubris Bio Pty Ltd
Dry Eye Disease (DED)
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
This is a Phase 2, randomized, multicenter, double masked, vehicle controlled, parallel group study to evaluate the efficacy and safety of DFL24498 topical ophthalmic solution versus vehicle in participants with dry eye disease.
- Trial name
- NCT07503886
- Testing
- DFL24498, Vehicle
- Where
- 24 sites in United States
- Volunteers
- 417 people
- Sponsor
- Dompé Farmaceutici S.p.A
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Dry Eye Disease
Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease
The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease.
- Trial name
- BUSTON-01 (NCT05865379)
- Testing
- BUFY01 eye drops in single-dose containers, SVS20 eye drops in single-dose containers
- Where
- 3 sites in Belgium, France
- Volunteers
- 80 people
- Sponsor
- TRB Chemedica International SA
Dry Eye Disease
Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease
The goal of this interventional investigation is to compare BUFY02 with TRB02 in the treatment of patients with dry eye disease.
- Trial name
- BUSTON-02 (NCT05865457)
- Testing
- BUFY02 eye drops in single-dose containers, TRB02 eye drops in single-dose containers
- Where
- 6 sites in Austria, France
- Volunteers
- 80 people
- Sponsor
- TRB Chemedica International SA
Myopia, Dry Eye Disease (DED)
Study of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs
The goal of this observational study is to investigate the effects of eye fatigue induced by screen task on dry eye disease (DED) signs and symptoms, visual performance, and visual behavior in young adults with and without DED…
- Trial name
- RReye (NCT07844408)
- Testing
- Eye Exams, Ocular Biometry and Aberrometry, Wearing a Smartwatch
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Essilor International
Dry Eye Disease (DED)
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
- Trial name
- PREDICT-1 (NCT07548632)
- Testing
- Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab
- Where
- 14 sites in United States
- Volunteers
- 160 people
- Sponsor
- Oculis
Dry Eye Disease
BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial
Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED.
- Trial name
- BRIGHT (NCT07778888)
- Testing
- BL1107
- Volunteers
- 20 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease (DED), Cataract Surgery
POST CATARACT SURGERY DRY EYE DISEASE
Cataract surgery is one of the most frequent and successful interventions currently undertaken in medicine. However, a significant number of patients who underwent cataract surgery still complain about postoperative symptoms…
- Trial name
- NCT07715266
- Testing
- NOX-01
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- NOXELIS
Dry Eye, Evaporative Dry Eye Disease
Microbiome-Focused Food Supplement for Evaporative Dry Eye Due to Meibomian Gland Dysfunction
Dry eye disease (DED) is a common chronic condition characterized by ocular surface discomfort and tear film instability. Evaporative DED associated with meibomian gland dysfunction (MGD) is a frequent phenotype and is often…
- Conditions
- Dry Eye, Evaporative Dry Eye Disease, Meibomian Gland Dysfunction (Disorder)
- Trial name
- NCT07453212
- Testing
- Dietary Supplement: Microbiome-targeted oral supplement
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 130 people
- Sponsor
- Varol TUNALI
Dry Eye Disease (DED)
Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease
Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.
- Trial name
- NCT07656688
- Testing
- HUC1-394
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Huons Co., Ltd.
Dry Eye Disease (DED)
Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease
A study to evaluate the effect of over- the- counter (OTC) lubricating eye drops on tolerability, symptoms and visual outcomes in patients with dry eye disease (DED)
- Trial name
- NCT07676084
- Testing
- Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Andover Research Eye Institute
Dry Eye Disease, Dry Eye
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for…
- Conditions
- Dry Eye Disease, Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes
- Trial name
- CAMOMILE-2 (NCT06903611)
- Testing
- CAM-101, Vehicle Control
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Cambium Bio Limited
Dry Eye Syndromes, Dry Eye
The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease
The central hypothesis is that inflammation contributes to dry eye and that rinsing the palpebral conjunctiva, bulbar conjunctiva, and fornices will reduce the inflammatory burden on the ocular surface.
- Conditions
- Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
- Trial name
- RINSE-A (NCT07618364)
- Testing
- Rinsada
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Rinsada
Dry Eye Syndromes, Dry Eye Disease (DED)
Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED
The goal of this clinical investigation plan is to evaluate the performance, tolerability, safety, and compliance of an ophthalmic solution containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV_01) compared…
- Trial name
- NCT07412860
- Testing
- FBV_01, HYLO-VISION® SafeDrop® Gel
- Where
- 2 sites in Italy
- Volunteers
- 74 people
- Sponsor
- FB Vision S.p.A
Dry Eye Disease (DED)
Efficacy and Safety of VMX Eye Drops for Dry Eye Disease
This multicenter, randomized, double-blind study evaluates the safety and effectiveness of VMX eye drops in patients with dry eye disease.
- Trial name
- NCT07369375
- Testing
- VMX Eye Drops
- Volunteers
- 76 people
- Sponsor
- VISUfarma SpA
Burning Eye, Irritation; Eyeball
Vit-A-Vision® Clinical Investigation
Symptoms of ocular discomfort include dryness, burning, stinging, photophobia, foreign body sensation and contact lens intolerance.
- Conditions
- Burning Eye, Irritation; Eyeball, Tired Eye, Dry Eye Disease
- Trial name
- NCT06596733
- Testing
- Vit-A-Vision
- Where
- Germany
- Volunteers
- 77 people
- Sponsor
- OmniVision GmbH
Dry Eye Disease (DED), Keratoconjunctivitis Sicca
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
- Trial name
- NCT07078955
- Testing
- BRM421 Ophthalmic Solution, 0.03%, Artificial Tear, BRM421 Ophthalmic Solution, 0.06%
- Where
- Taiwan
- Volunteers
- 99 people
- Sponsor
- BRIM Biotechnology Inc.
Healthy, Dry Eyes
Topical Menthol For Tear Secretion
Tears are the natural way to keep eyes moist, and tears are important for good vision and healthy eyes. Eyes without enought tears get dry and sore.
- Trial name
- TMTS (NCT07109609)
- Testing
- Topical application of 20% menthol solution in MCT oil.
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Reinhold Vieth
Dry Eye Disease (DED)
A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
The objective of this study is to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution twice a day (BID) and four times a day (QID) compared to placebo (vehicle) in the treatment of the signs and symptoms of dry…
- Trial name
- NCT07068958
- Testing
- 0.25% RCI001 Ophthalmic Solution
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.